News Merck makes its move: Keytruda filed for first line lung can... Merck steals a march on rival BMS.
News BMS' Opdivo stumbles in lung cancer, but could still maintai... Analysts expect Opdivo to recover via combination trials
News Scotland's Opdivo decision sparks funding row Patients in Scotland will receive lung cancer drug, those in England will not.
Articles AstraZeneca, Genentech fund PatientsLikeMe research into can... PatientsLikeMe is working with AstraZeneca and Roche to find about more about the experiences of people being treated for lung cancer
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.